Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CureVac (CVAC) Receivables - Net (2019 - 2025)

Historic Receivables - Net for CureVac (CVAC) over the last 7 years, with Q3 2025 value amounting to $22.9 million.

  • CureVac's Receivables - Net rose 26195.6% to $22.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.9 million, marking a year-over-year increase of 26195.6%. This contributed to the annual value of $15.0 million for FY2024, which is 240.89% down from last year.
  • Per CureVac's latest filing, its Receivables - Net stood at $22.9 million for Q3 2025, which was up 26195.6% from $462971.5 recorded in Q2 2025.
  • CureVac's 5-year Receivables - Net high stood at $22.9 million for Q3 2025, and its period low was $7065.1 during Q1 2022.
  • Moreover, its 5-year median value for Receivables - Net was $6.3 million (2024), whereas its average is $8.6 million.
  • As far as peak fluctuations go, CureVac's Receivables - Net crashed by 9989.04% in 2023, and later skyrocketed by 12946536.09% in 2024.
  • CureVac's Receivables - Net (Quarter) stood at $21.2 million in 2021, then crashed by 69.66% to $6.4 million in 2022, then surged by 140.0% to $15.4 million in 2023, then fell by 2.41% to $15.0 million in 2024, then surged by 52.32% to $22.9 million in 2025.
  • Its Receivables - Net stands at $22.9 million for Q3 2025, versus $462971.5 for Q2 2025 and $2.0 million for Q1 2025.